Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

Arjun Balar, MD
Published: Friday, Feb 17, 2017



Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-052 trial in cisplatin-ineligible advanced urothelial carcinoma.

In this study of 370 patients, 200 mg of pembrolizumab (Keytruda) was administered every 3 weeks. At week 9, imaging was performed and then every 6 weeks for the first year and every 12 weeks beyond that.

The study met its primary end point of overall response rate, which was 27% among patients with a greater than 4-month follow-up. The complete response rate was 6%.

Balar concludes that this study confirms the effectiveness and durability of pembrolizumab in cisplatin-ineligible patients with urothelial carcinoma.
 


Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-052 trial in cisplatin-ineligible advanced urothelial carcinoma.

In this study of 370 patients, 200 mg of pembrolizumab (Keytruda) was administered every 3 weeks. At week 9, imaging was performed and then every 6 weeks for the first year and every 12 weeks beyond that.

The study met its primary end point of overall response rate, which was 27% among patients with a greater than 4-month follow-up. The complete response rate was 6%.

Balar concludes that this study confirms the effectiveness and durability of pembrolizumab in cisplatin-ineligible patients with urothelial carcinoma.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x